July 23, 2025

Table 2 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Chemoimmunotherapy shows potential to improve overall survival in advanced low PD-L1 non-small cell lung cancer.
Analysis suggests PD-L1 expression is a significant prognostic factor for treatment outcomes.
Multivariate analysis was used to evaluate outcomes in patients undergoing immune checkpoint inhibitors alongside chemotherapy.
Understanding these factors can inform treatment decisions and improve patient care in lung cancer.

Implication

Univariate and multivariate analysis reveals outcomes in patients with non-small cell lung cancer, indicating the role of PD-L1 expression.

Univariate and multivariate analysis of OS in patients treated with ICI and chemotherapy

No takes yet. Share an insight, caveat, or question.

Hata et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Univariate and multivariate analysis reveals outcomes in patients with non-small cell lung cancer, indicating the role of PD-L1 expression.

Univariate and multivariate analysis of OS in patients treated with ICI and chemotherapy